September 2021 in “GLOBAL JOURNAL FOR RESEARCH ANALYSIS” The hormonal contraceptive combination effectively reduces androgen excess and improves PCOS symptoms like acne, hair loss, and menstrual issues.
17 citations
,
June 1996 in “The Journal of Steroid Biochemistry and Molecular Biology” FCE 28260 is a stronger and longer-lasting inhibitor of 5α-reductase than finasteride, which may make it a better treatment for certain medical conditions.
4 citations
,
October 2000 in “Contraception” The right dosage of CPA and TB can work as a safe and reversible male contraceptive in monkeys.
April 2018 in “Radiotherapy and Oncology” Prostaglandin helps regenerate hair follicles after radiation damage.
January 2009 in “Journal of Xingtai University” Finasteride is made through a series of chemical reactions starting from a specific intermediate compound.
42 citations
,
July 2021 in “Frontiers in Medicine” Proxalutamide significantly lowered hospital admissions for male COVID-19 patients compared to a placebo.
88 citations
,
September 2003 in “Clinical endocrinology” Hormone treatment for transsexual individuals is effective but carries risks like thromboembolic events and mood changes, with most side effects being minor and reversible.
January 1978 in “Enlighten: Theses (The University of Glasgow)” Inhibiting testosterone 5alpha-reductase may help treat benign prostatic hyperplasia.
65 citations
,
October 2008 in “Journal of Neuroendocrinology” 1 citations
,
July 2022 in “Frontiers in Pharmacology” Dutasteride may help protect neurons and reduce inflammation in Parkinson's disease.
2 citations
,
February 2022 in “Frontiers in Endocrinology” Antiandrogenic pretreatment for women with PCOS does not improve fertility outcomes and delays pregnancy.
Mesotherapy with dutasteride effectively treats hair loss with manageable side effects.
March 2005 in “The Nurse Practitioner”
January 2025 in “Brazilian Journal of Veterinary Medicine/Revista Brasileira de Medicina Veterinária” Deslorelin implant successfully regrew hair in a female Pomeranian with alopecia X.
April 2023 in “Journal of Investigative Dermatology” cp-asiAR may effectively treat hair loss by targeting androgen receptors.
35 citations
,
July 2008 in “International Journal of Gynecology & Obstetrics” MPA improved hormonal imbalances and acne in women with PCOS without affecting metabolism.
July 2016 in “Reactions Weekly” Cyproterone and finasteride reduced hypersexuality but caused serious side effects.
3 citations
,
October 1994 in “Journal of Labelled Compounds and Radiopharmaceuticals” Scientists made a carbon-14 labeled version of a drug with a 48% yield and over 99% purity.
Dutasteride may become the top choice for treating hair loss.
July 2014 in “Urologia Journal” 5ARI treatment improves PSA test accuracy for prostate cancer diagnosis.
8 citations
,
May 2020 in “Arthritis research & therapy” DHT inhibition may increase spinal bone growth in ankylosing spondylitis.
January 2004 in “Drug Development and Industrial Pharmacy” GI197111X is best dissolved in Capmul MCM for trials.
11 citations
,
May 2015 in “Stem Cells Translational Medicine” Megestrol acetate helps fat-derived stem cells grow, move, and turn into fat cells through a specific receptor.
July 2024 in “Journal of Investigative Dermatology” ATR12-351 ointment safely delivers LEKTI protein to the skin, reducing enzyme activity in Netherton syndrome.
17 citations
,
June 2012 in “European journal of medicinal chemistry” New steroid compounds effectively inhibit 5α-reductase and may treat hair loss.
28 citations
,
May 1986 in “Clinics in endocrinology and metabolism” New compounds may soon be tested to treat excessive hair growth in women.
July 2026 in “Journal of Medicinal Chemistry” A new drug strategy improves hair loss treatment with better results and safety.
31 citations
,
January 1989 in “The Prostate/The prostate” Estradiol and castration reduced prostate cancer development in rats when applied at early stages, but were ineffective after cancer was established.
37 citations
,
April 2008 in “The Cochrane library” 5-alpha-reductase inhibitors can lower prostate cancer risk but may increase high-grade tumors and cause sexual side effects.
May 2026 in “Frontiers in Pharmacology” Long-term use of 5α-reductase inhibitors may improve survival in men with kidney cancer.